Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunization Products Limited

Executive Summary

Elizabeth Corsi appointed VP and general manager of the newly- formed operational unit for the Rhone-Poulenc Rorer/Immune Response Corp. joint venture for an AIDS vaccine. Results of Phase II/III trials of the AIDS immunotherapeutic (the "Salk vaccine") are now being compiled and should be unblinded by early next year. A PLA will be filed in 1993 if the results are positive. Production capacities are being scaled up for commercial production of the vaccine.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS021806

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel